Diabetes care products boost Novo Nordisk's sales in 1996
This article was originally published in Clinica
Danish company Novo Nordisk's healthcare business recorded sales of DKr 11,078 million ($1,696 million), up 12%, in 1996. The healthcare and enzyme company reported 15% sales growth for its diabetes products, to DKr 7,784 million. This growth is due to increased sales of its Penfill for NovoPen injectors and the disposable NovoLet delivery system. Sales in the US and Asia, particularly Japan, were good. Group turnover was up 8% to DKr 14,873 million, and net income rose 15% to DKr 1,799 million.
You may also be interested in...
According to the plaintiff, Unilever’s Pond’s Rejuveness Anti-Wrinkle Cream is defective insofar as tested product has been found to contain unlabeled mercury, constituting negligence that has resulted in user injuries. The plaintiff seeks certification of a transnational class and compensatory and punitive damages, among other relief.
HBW Product Launches: New Chapter Collagen, Alkamind Acid-Kicking, GNC China, Tetra Bio Canada, More
GNC, Harbin launch supplements in China following regulatory approval; Bee Gone expands with allergy swabs; Bed, Bath & Beyond expands distribution of CBDMedic personal care products promoted by Rob Gronkowski; Tetra Bio has Canadian OK For hemorrhoid and pain relief OTCs, US and European pending; Agrozen offers Urban Daze CBD products; New Chapter portfolio expansion also includes fermented vitamins, elderberry supplements and magnesium; and Alkamind’s Acid-Kicking Coffee Alkalizer creamers help neutralize acid from coffee.
In joint complaint, the FTC and New York Attorney General allege scheme to block generic Daraprim and maintain exorbitant list price; they cite hundreds of emails the incarcerated Shkreli has exchanged with co-defendant in last six months.